No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
www.donga-st.comNo one on the platform currently holds 170900.KS.
No tracked institution reports a position in 170900.KS as of their last filing.
No one on the platform has traded 170900.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 15.9% | 6.6% | ||||
| Profit Margin % | -3.5% | 0.5% | 2.1% | |||
| Free Cash Flow Margin % | -1.2% | -4.9% | -1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $853.5B | +16.7% | $3488.75 | $3377.61–$3599.89 | — | 2 |
| 2027 | $926.6B | +8.6% | $3881.75 | $3147.21–$5306.44 | — | 3 |
| 2028 | $1.01T | +8.6% | $4466.50 | $4466.50–$4466.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-04-30 | $1069.59 | $-1347.00 | -225.9% |
| 2024-11-01 | $1311.19 | $-3107.00 | -337.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 170900.KSDong-A ST Co., Ltd. | $36000.00 | -1.37% | $347.2B | — |
| 001060.KSJW Pharmaceutical Corporation | $27100.00 | +0.00% | $625.8B | — |
| 001065.KSJW Pharmaceutical Corporation | $22350.00 | -0.22% | $394.3B | — |
| 001067.KSJW Pharmaceutical Corporation | $48350.00 | -0.10% | $447.2B | — |
| 003000.KSBukwang Pharmaceutical Co., Ltd. |
| $3845.00 |
| -1.16% |
| $379.4B |
| — |
| 003520.KSYungjin Pharm. Co., Ltd. | $1040.00 | -0.29% | $190.2B | — |
| 047920.KQHLB Pharmaceutical Co., Ltd | $6700.00 | +3.88% | $219.8B | — |
Source: Financial Modeling Prep · peers by sector/industry